References
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–9.
- Zhou R, Peng N, Li W. Constructing a novel gene signature derived from oxidative stress specific subtypes for predicting survival in stomach adenocarcinoma. Front Immunol. 2022;13:964919.
- Li K, Zhang A, Li X, et al. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188615.
- Sun Z, Zhao Y, Wei Y, et al. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma. Front Immunol. 2022;13:939523.
- Majidpoor J, Mortezaee K. Steps in metastasis: an updated review. Med Oncol. 2021;38:3.
- Xing C, Sun SG, Yue ZQ, et al. Role of lncRNA LUCAT1 in cancer. Biomed Pharmacother. 2021;134:111158.
- Loewer S, Cabili MN, Guttman M, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42:1113–1117.
- Gupta RA, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–1076.
- Venkatraman A, et al. Maternal imprinting at the H19–Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature. 2013;500(7462):345–349. DOI:10.1038/nature12303
- Li J, Meng H, Bai Y, et al. Regulation of lncRNA and its role in cancer metastasis. Oncol Res. 2016;23:205–217.
- Dai W, Tian C, Jin S. Effect of lncRNA ANRIL silencing on anoikis and cell cycle in human glioma via microRNA-203a. Onco Targets Ther. 2018;11:5103–5109.
- Seitz AK, et al. Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. Sci Rep. 2017;7:395.
- Adeshakin FO, et al. Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming. Front Oncol. 2021;11:626577.
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140.
- Sengupta RBD Modeling survival data: extending the cox model by terry m. Therneau; Patricia MG. Modeling Survival Data: Extending the Cox Model by Terry M. Sankhya Ser A. 2003;65:843–844. Therneau.
- Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized Linear Models via Coordinate Descent. J Stat Softw. 2010;33(1):1–22.
- Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381–5397.
- Huang C, Liu Z, Xiao L, et al. Clinical significance of serum ca125, ca19-9, ca72-4, and fibrinogen-to-lymphocyte ratio in gastric cancer with peritoneal dissemination. Front Oncol. 2019;9:1159.
- Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.
- Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
- Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14:7.
- Buchbinder EI, Desai A. ***CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.
- Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541(7637):321–330.
- Wang N, Liu D. Identification and validation a necroptosis related prognostic signature and associated regulatory axis in stomach adenocarcinoma. Onco Targets Ther. 2021;14:5373–5383.
- Jin D, Song Y, Chen Y, et al. Identification of a seven-lncRNA immune risk signature and construction of a predictive nomogram for lung adenocarcinoma. Biomed Res Int. 2020;2020:1–17.
- Li N, et al. Long non-coding RNA ADAMTS9-AS1 suppresses colorectal cancer by inhibiting the wnt/beta-catenin signalling pathway and is a potential diagnostic biomarker. J Cell Mol Med. 2020;24:11318–11329.
- Liu GX, Tan YZ, He GC, et al. EMX2OS plays a prognosis-associated enhancer RNA role in gastric cancer. Medicine (Baltimore). 2021;100:e27535.
- Bartl J, et al. The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. Nat Commun. 2022;13:4061.
- Li Z, Yang AJ, Wei FM, et al. Significant association of DIRC1 overexpression with tumor progression and poor prognosis in gastric cancer. Eur Rev Med Pharmacol Sci. 2018;22:8682–8689.
- Zhao Q, et al. Immunotherapy for gastric cancer: dilemmas and prospect. Brief Funct Genomics. 2019;18:107–112.
- Zeng C, et al. Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma. Front Genet. 2022;13:935056.
- Chen S, Gu J, Zhang Q, et al. Development of biomarker signatures associated with anoikis to predict prognosis in endometrial carcinoma patients. J Oncol. 2021;2021:3375297.
- Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503.